


CLAIMS

1. A compound of formula (I)



5 [wherein

R^1 and R^2 are each independently, an acidic group which may be protected,

D and E are each independently, a bond or a spacer consisting of 1-8 of atom in the main chain,

10 R^3 is a substituent,


ring A is a cyclic group which may have further substituent(s),

ring B is a cyclic group which may have further substituent(s),

15 Y and Z are each independently, a carbon atom or a nitrogen atom, and


----- is a single bond or a double bond (provided that Y and/or Z is/are nitrogen atom(s), the bond is a single bond.).], an N-oxide thereof, a salt thereof, a solvate
20 thereof or a prodrug thereof.

2. The compound according to claim 1, wherein



is 3,4-dihydro-2H-1,4-benzoxazine, 3,4-dihydro-2H-1,4-benzothiazine, 1,2,3,4-tetrahydroquinoxaline, 1,2,3,4-tetrahydroquinoline, 1,2-dihydroquinoline, 4H-1,4-benzoxazine, 4H-1,4-benzothiazine, quinoline, isoquinoline, quinoxaline, 1,2,3,4-tetrahydroisoquinoline, cinnoline, phthalazine, 4(1H)-quinolinone, 3,4-dihydro-2(1H)-quinolinone, 2(1H)-quinolinone, 1H-indole or indoline ring.

3. The compound according to claim 1, wherein R^3 is



(wherein

ring 1 is a cyclic group which may have substituent(s),

V is a bond or a spacer having 1-8 of atom in the main chain,


ring 2 is a cyclic group which may have substituent(s),

and


W is a bond or a spacer having 1-8 of atom in the main chain).

4. The compound according to claim 1, wherein the acidic group represented by R^1 and R^2 are each independently, $-\text{COOR}^A$ (wherein R^A is hydrogen or C1-8 alkyl), $-\text{CONR}^B\text{SO}_2\text{R}^C$ (wherein R^B is hydrogen or C1-8 alkyl, R^C is C1-8

hydrocarbon), $-\text{SO}_2\text{NR}^{\text{B}}\text{COR}^{\text{C}}$ (wherein all symbols have the same meanings as described hereinbefore),



- 5 5. The compound according to claim 1, which is a compound of formula (I-X)



(wherein R^{30} is hydrogen or a substituent, m is 0 or an integer of 1 to 4, L is a nitrogen atom, an oxygen atom, a sulfur atom which may be oxidized, a carbon atom or a bond, and the other symbols have the same meanings as in claims 1 and 3, and the adjacent two
 ----- bonds do not represent a double bond at the same
 15 time.).

6. The compound according to claim 3 or claim 5, wherein V is a divalent group comprising the combination of 1-4 member(s) selected from $-\text{CH}_2-$ optionally having 1-2 of substituent, $-\text{CH}=\text{CH}-$ optionally having 1-2 of substituent, $-\text{C}=\text{C}-$, $-\text{NH}-$ optionally having a substituent, $-\text{CO}-$, $-\text{O}-$, $-\text{S}-$, $-\text{SO}-$ and SO_2- .


7. The compound according to claim 3 or claim 5, wherein -D-R¹ is -CO-(CH₂)₂-R¹, -CO-(CH₂)₃-R¹, -CO-(CH₂)₄-R¹ or C1-4 alkylene-R¹.

5

8. The compound according to claim 3 or claim 5 wherein E is a bond or C1-4 alkylne.

9. The compound according to claim 3 or claim 5, wherein V is

10



10. The compound according to claim 1, which is selected from

15

(1) 4-(3-carboxypropyl)-8-((4-(4-phenylbutoxy)benzoyl)amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

20

(2) 4-(3-carboxypropyl)-8-((2E)-3-[4-(4-phenylbutyl)phenyl]-2-propenoyl)amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(3) 4-[8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,

25

(4) 4-(3-carboxypropyl)-8-[[4-(4-phenylbutoxy)benzyl]amino]-3,4-dihydro-2H-1,4-benzoxazine-2-

carboxylic acid,

(5) 4-(3-carboxypropyl)-8-[(E)-2-[4-(4-phenylbutoxy)phenyl]vinyl]-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

5 (6) 4-(3-carboxypropyl)-8-[2-[4-(4-phenylbutoxy)phenyl]ethyl]-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(7) (2S)-4-(3-carboxypropyl)-8-[[4-(4-phenylbutoxy)benzoyl]amino]-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(8) (2R)-4-(3-carboxypropyl)-8-[[4-(4-phenylbutoxy)benzoyl]amino]-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(9) 4-(3-carboxypropyl)-8-([4-[2-(2,3-dihydro-1H-inden-15 2-yl)ethoxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(10) 4-(3-carboxypropyl)-8-([4-[(5-phenylpentyl)oxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

20 (11) 4-(3-carboxypropyl)-8-([4-[(7-phenylheptyl)oxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(12) 4-(3-carboxypropyl)-8-([4-[(4-methylpentyl)oxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

25 (13) 4-(3-carboxypropyl)-8-[[4-(4-phenoxybutoxy)benzoyl]amino]-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

- (14) 4-(3-carboxypropyl)-8-({4-[3-(2,3-dihydro-1H-inden-2-yl)propoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (15) 4-(3-carboxypropyl)-8-({4-[4-(4-fluorophenyl)butoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (16) 4-(3-carboxypropyl)-8-({4-[4-(2-methylphenoxy)butoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (17) 4-(3-carboxypropyl)-8-({4-[4-(2-fluorophenoxy)butoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (18) 4-(3-carboxypropyl)-8-({4-[4-(2-chlorophenoxy)butoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (19) 4-(3-carboxypropyl)-8-[(4-{4-[2-(trifluoromethyl)phenoxy]butoxy}benzoyl)amino]-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (20) 4-(3-carboxypropyl)-8-({4-[3-(2-methylphenoxy)propoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (21) 4-(2-({[(4-methylphenyl)sulfonyl]amino}carbonyl))-8-([4-(4-phenylbutoxy)benzoyl]amino)-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,
- (22) 4-(2-({[(methylsulfonyl)amino]carbonyl}))-8-([4-(4-phenylbutoxy)benzoyl]amino)-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,
- (23) 4-(2-({[(benzylsulfonyl)amino]carbonyl}))-8-([4-(4-

phenylbutoxy)benzoyl]amino}-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,

(24) 4-(3-carboxypropyl)-8-((E)-2-[4-(4-phenoxybutoxy)phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(25) 4-(3-carboxypropyl)-8-((E)-2-[4-(2,3-dihydro-1H-inden-2-ylmethoxy)phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(26) 4-(3-carboxypropyl)-8-((E)-2-[4-[3-(2,3-dihydro-1H-inden-2-yl)propoxy]phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(27) 4-(3-carboxypropyl)-8-((E)-2-[4-[(5-phenoxypropyl)oxy]phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(28) 4-(3-carboxypropyl)-8-((E)-2-[4-(4-methoxyphenoxy)butoxy]phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(29) 4-(3-carboxypropyl)-8-((E)-2-[4-[3-(4-fluorophenoxy)propoxy]phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(30) 4-(3-carboxypropyl)-8-((E)-2-[4-(3-phenoxypropoxy)phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(31) 4-(3-carboxypropyl)-8-((E)-2-[4-[3-(2-chlorophenoxy)propoxy]phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(32) 4-(3-carboxypropyl)-8-((E)-2-[4-(4-phenoxybutoxy)phenyl]ethyl)-3,4-dihydro-2H-1,4-benzoxazine-2-

carboxylic acid,

(33) 4-[8-{2-[4-(4-phenylbutoxy)phenyl]ethyl}-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,

5 (34) 4-[8-{(E)-2-[4-(4-phenylbutoxy)phenyl]vinyl}-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,

(35) 4-(2-(5-oxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)-8-
10 {[4-(4-phenylbutoxy)benzoyl]amino}-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,

(36) 4-(2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-8-
{(E)-2-[4-(4-phenylbutoxy)phenyl]vinyl}-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,

(37) 4-oxo-4-(8-((4-(4-phenylbutoxy)benzoyl)amino)-2-
15 (1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid, and

(38) 4-(3-carboxypropyl)-8-((4-(4-phenylbutoxy)benzyl)oxy)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid.

20

11. A pharmaceutical composition comprising the compound of formula (I), an N-oxide thereof, a salt thereof, a solvate thereof or a prodrug thereof according to claim 1.

25 12. The pharmaceutical composition according to claim 11, which is an agent for the prevention and/or treatment of a disease mediated by cysLT₂.

13. The pharmaceutical composition according to claim 12, wherein the disease mediated by cysLT₂ is a respiratory disease.

5 14. The pharmaceutical composition according to claim 13, wherein the respiratory disease is asthma or chronic obstructive pulmonary disease.

15 15. A medicine comprising the compound of formula (I), an N-oxide thereof, a salt thereof, a solvate thereof or a prodrug thereof according to claim 1 and one or more member(s) selected from a cysLT₁ receptor antagonist, a steroidal agent, an antihistamine agent, a phosphodiesterase 4 inhibitor, an elastase inhibitor, an anticholinergic agent and a sympathomimetic agent.

16. A method for the prevention and/or treatment of the diseases mediated by cysLT₂, characterized by administering to a mammal an effective amount of the compound of formula (I), an N-oxide thereof, a salt thereof, a solvate thereof or a prodrug thereof according to claim 1.

17. A method for the prevention and/or treatment of the diseases mediated by cysLT₂, characterized by administering to a mammal an effective amount of the compound of formula (I), an N-oxide thereof, a salt thereof, a solvate thereof or a prodrug thereof according to claim 1, in combination with a cysLT₁ receptor antagonist, a steroidal agent, an

antihistamine agent, a phosphodiesterase 4 inhibitor, an elastase inhibitor, an anticholinergic agent and a sympathomimetic drug.

- 5 18. Use of the compound of formula (I) according to claim 1, for the manufacture of an agent for the prevention and/or treatment of the disease mediated by cysLT_2 .